CA3065683A1 - Method for producing optically active compound - Google Patents

Method for producing optically active compound Download PDF

Info

Publication number
CA3065683A1
CA3065683A1 CA3065683A CA3065683A CA3065683A1 CA 3065683 A1 CA3065683 A1 CA 3065683A1 CA 3065683 A CA3065683 A CA 3065683A CA 3065683 A CA3065683 A CA 3065683A CA 3065683 A1 CA3065683 A1 CA 3065683A1
Authority
CA
Canada
Prior art keywords
group
optionally substituted
salt
acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3065683A
Other languages
English (en)
French (fr)
Inventor
Sayuri HIRANO
Yoshiyuki Takeda
Koji Nakamoto
Motoki Ikeuchi
Masato Kitayama
Masatoshi Yamada
Jun-Ichi Kawakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Day One Biopharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA3065683A1 publication Critical patent/CA3065683A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3065683A 2017-05-30 2018-05-29 Method for producing optically active compound Pending CA3065683A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017106280 2017-05-30
JP2017-106280 2017-05-30
PCT/IB2018/053822 WO2018220533A2 (ja) 2017-05-30 2018-05-29 光学活性化合物の製造法

Publications (1)

Publication Number Publication Date
CA3065683A1 true CA3065683A1 (en) 2018-12-06

Family

ID=64454503

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065683A Pending CA3065683A1 (en) 2017-05-30 2018-05-29 Method for producing optically active compound

Country Status (12)

Country Link
US (2) US10988469B2 (enExample)
EP (2) EP3632441B1 (enExample)
JP (2) JP7102233B2 (enExample)
KR (1) KR102754527B1 (enExample)
CN (2) CN117447464A (enExample)
AU (1) AU2018276192B2 (enExample)
CA (1) CA3065683A1 (enExample)
EA (1) EA039880B1 (enExample)
ES (1) ES2986461T3 (enExample)
IL (1) IL270983B (enExample)
MX (1) MX391164B (enExample)
WO (1) WO2018220533A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102754527B1 (ko) 2017-05-30 2025-01-14 데이 원 바이오파마슈티칼즈, 인크. 광학 활성 화합물의 제조법
EP3950672A4 (en) * 2019-03-27 2023-01-11 Kyowa Pharma Chemical Co., Ltd. PROCESS FOR PRODUCTION OF PROSTAGLANDIN
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma
CN114685564B (zh) * 2020-12-27 2023-09-22 西北大学 新型亚磷酰胺配体及其合成方法和应用
CN117715889A (zh) 2021-07-26 2024-03-15 阿尔维纳斯运营股份有限公司 制备双官能化合物的方法
CN117567388B (zh) * 2023-11-14 2024-04-16 济南悟通生物科技有限公司 一种2-乙酰基-5-噻唑甲酸的合成方法
CN119241530A (zh) * 2024-09-20 2025-01-03 武汉九州钰民医药科技有限公司 一种Tovorafenib的药物合成工艺
CN119241529A (zh) * 2024-09-20 2025-01-03 武汉九州钰民医药科技有限公司 一种Tovorafenib的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764842B2 (en) * 2001-03-28 2004-07-20 Merck & Co., Inc. Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
CA2694284A1 (en) * 2007-06-29 2009-01-08 Jennifer Cossrow Heterocyclic compounds useful as raf kinase inhibitors
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
EP3680240A1 (en) * 2012-03-14 2020-07-15 Merck Sharp & Dohme Corp. Asymmetric phase transfer catalysis
WO2013146987A1 (ja) 2012-03-28 2013-10-03 武田薬品工業株式会社 ロジウム触媒及びアミン化合物の製造法
TWI602803B (zh) * 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
WO2015178846A1 (en) * 2014-05-20 2015-11-26 Sp Process Development Ab Process for the preparation of chiral amines from prochiral ketones
JP6638363B2 (ja) 2015-12-11 2020-01-29 株式会社大林組 掘削装置および杭孔の拡径方法
CN105524111B (zh) * 2016-01-25 2017-10-27 西北农林科技大学 手性亚磷酰胺单齿配体及其合成方法与应用
KR102754527B1 (ko) 2017-05-30 2025-01-14 데이 원 바이오파마슈티칼즈, 인크. 광학 활성 화합물의 제조법

Also Published As

Publication number Publication date
US20200317659A1 (en) 2020-10-08
AU2018276192A1 (en) 2020-01-16
CN117447464A (zh) 2024-01-26
EP3632441C0 (en) 2024-07-17
EA039880B1 (ru) 2022-03-23
EA201992709A1 (ru) 2020-04-23
IL270983B (en) 2022-03-01
AU2018276192B2 (en) 2022-05-19
US10988469B2 (en) 2021-04-27
MX2019014256A (es) 2022-03-31
JP2022116043A (ja) 2022-08-09
JP2018203733A (ja) 2018-12-27
KR102754527B1 (ko) 2025-01-14
EP4406609A2 (en) 2024-07-31
US20210347769A1 (en) 2021-11-11
CN111032047A (zh) 2020-04-17
EP3632441A4 (en) 2021-01-13
JP7420865B2 (ja) 2024-01-23
KR20200013707A (ko) 2020-02-07
JP7102233B2 (ja) 2022-07-19
MX391164B (es) 2025-03-21
BR112019025355A2 (pt) 2020-06-23
WO2018220533A3 (ja) 2019-02-28
WO2018220533A2 (ja) 2018-12-06
US12129249B2 (en) 2024-10-29
EP3632441A2 (en) 2020-04-08
CN111032047B (zh) 2023-10-27
EP4406609A3 (en) 2024-10-02
ES2986461T3 (es) 2024-11-11
EP3632441B1 (en) 2024-07-17
IL270983A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
JP7420865B2 (ja) 光学活性化合物の製造法
DK2411385T3 (en) PROCESS FOR THE PREPARATION OF propionic acid derivatives
JP2005516036A6 (ja) 非ラセミｓｙｎ−１−（４−ヒドロキシ−フェニル）−２−（４−ヒドロキシ−４−フェニル−ピペリジン−１−イル）−１−プロパノ−ル化合物の製造方法
JP2005516036A (ja) 非ラセミｓｙｎ−１−（４−ヒドロキシ−フェニル）−２−（４−ヒドロキシ−４−フェニル−ピペリジン−１−イル）−１−プロパノ−ル化合物の製造方法
US20180079741A1 (en) Process for producing heterocyclic compound
HK40114634A (en) Method for producing optically active compound
HK40022701A (en) Method for producing optically active compound
CN111417618B (zh) 用于制备富含对映异构体和非对映异构体的环丁烷胺和环丁烷酰胺的方法
BR112019025355B1 (pt) Métodos para a produção de compostos oticamente ativos, composto e forma oticamente ativa
HK40022701B (en) Method for producing optically active compound
CA2783448A1 (en) Process for the preparation of propionic acid derivatives
RU2793738C2 (ru) Способ получения энантиомерно и диастереомерно обогащенных циклобутанаминов и -амидов

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230529

EEER Examination request

Effective date: 20230529

EEER Examination request

Effective date: 20230529